Revised International Staging System (R-ISS) for multiple myeloma
The revised staging system for myeloma combines the older albumin and beta-2 microglobulin stage with high-risk chromosome changes and a raised lactate dehydrogenase, giving three groups with very different survival.
Overview
Analysis of 3,060 patients from eleven international trials to build a staging system combining ISS stage, chromosomal abnormalities detected by fluorescence in situ hybridisation (del(17p), t(4;14), t(14;16)) and serum lactate dehydrogenase.
Five-year overall survival was 82 percent in R-ISS stage I, 62 percent in stage II and 40 percent in stage III. The R-ISS became the standard prognostic framework and the basis for trial stratification.
- Five-year overall survival 82, 62 and 40 percent in stages I, II and III.
- Five-year progression-free survival 55, 36 and 24 percent.
The stage on a myeloma report, and the label of high-risk disease that drives intensified treatment and trial choice, comes from the R-ISS; the 2022 R2-ISS adds 1q gain.
- Stage II is a large heterogeneous group.
- Derived from trial patients treated with older regimens.
Similar pages
not linked directly; found by shared links- Key paperIFM 2006 prospective trial: bortezomib-based induction and transplantation for primary plasma cell leukaemia
- TargetProteasome (PSMB5)
Shares Plasma cell leukaemia, Newly diagnosed multiple myeloma, transplant-eligible.
- TermProteasome inhibitor (bortezomib, carfilzomib, ixazomib)
Shares Plasma cell leukaemia, Newly diagnosed multiple myeloma, transplant-eligible, Relapsed or refractory multiple myeloma.
- TermHigh-risk cytogenetics (myeloma)
Shares Plasma cell leukaemia, Newly diagnosed multiple myeloma, transplant-eligible.
- TargetCereblon (CRBN)
Shares Newly diagnosed multiple myeloma, transplant-eligible, Relapsed or refractory multiple myeloma.
- TermM-protein, immunofixation and serum free light chains
Shares Plasma cell leukaemia, Newly diagnosed multiple myeloma, transplant-eligible, Relapsed or refractory multiple myeloma.
- Termt(11;14), cyclin D1 and SOX11
Shares Plasma cell leukaemia, Relapsed or refractory multiple myeloma.
- TermImmunomodulatory drugs (IMiDs) and CELMoDs
Shares Newly diagnosed multiple myeloma, transplant-eligible, Relapsed or refractory multiple myeloma.